secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2025-09-02T23:59:59+00:00
Accession:  0001213900-25-082956
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix completes $300M acquisition of Melinta; raises FY2025 revenue guidance
-------------------------------------------------------------------------------

- Acquisition closed Aug 29, 2025; $260M cash + $40M equity upfront, plus up to $25M in milestone payments.
- Pro forma 2025 revenue guidance raised to $325-350M; synergies expected $35-45M annually.
- Transaction expected near-term accretive to EPS with double-digit accretion in 2026.
- Susan Blum appointed CFO, Elizabeth Hurlburt COO, Matthew David CBO effective immediately.
- Contingent payments include tiered royalties on REZZAYO US net sales and low-single-digit royalties on MINOCIN US net sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390025082956/0001213900-25-082956-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390025082956/ea0255371-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-082956

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer